{"id":14499,"date":"2023-02-24T15:32:56","date_gmt":"2023-02-24T08:32:56","guid":{"rendered":"https:\/\/hpsp-prod.th1.proen.cloud\/%e0%b8%a1%e0%b8%b0%e0%b9%80%e0%b8%a3%e0%b9%87%e0%b8%87%e0%b8%95%e0%b8%b1%e0%b8%9a\/"},"modified":"2023-03-06T15:29:30","modified_gmt":"2023-03-06T08:29:30","slug":"liver-cancer","status":"publish","type":"post","link":"https:\/\/hpsp.or.th\/en\/liver-cancer\/","title":{"rendered":"Liver cancer"},"content":{"rendered":"

[vc_row][vc_column][vc_column_text]Our clinical trial<\/strong> : Hepatocellular Carcinoma<\/span><\/p>\n

Trial status <\/strong>: recruiting<\/span><\/p>\n

First posted <\/strong>: 30 January 2023<\/span><\/p>\n

Last updated <\/strong>: 30 January 2023<\/span><\/p>\n

\u00a0<\/span><\/p>\n

Full Title<\/strong><\/p>\n

Multi-institutional study: Phase III randomized controlled trial between stereotactic body radiotherapy (SBRT) vs stereotactic body proton therapy (SBPT) and for unresectable hepatocellular carcinoma<\/span>[\/vc_column_text][\/vc_column][\/vc_row][vc_row full_width=”stretch_row” content_placement=”middle” css=”.vc_custom_1678088610158{background-color: #eff3fa !important;}”][vc_column width=”1\/2″][vc_column_text]Purpose<\/strong><\/p>\n

Local therapy options for HCC include transplantation, surgical resection, ablative procedures, and radiation therapy. Surgery remains the gold standard, but many patients are technically or medically inoperable. Historically, the efficacy of RT in liver cancer has been limited by low liver tolerance to whole liver irradiation. The most concerning and dose-limiting toxicity of liver radiation is a radiation-induced liver disease (RILD) because it can lead to liver failure and death. As a result, RT played a minor role in managing liver tumors. However, recent advances in radiation planning and delivery technology have facilitated safer delivery of ablative radiation therapy doses, which are increasingly used for HCC.<\/span>[\/vc_column_text][\/vc_column][vc_column width=”1\/2″][vc_single_image image=”14960″ img_size=”full” style=”vc_box_shadow_border”][\/vc_column][\/vc_row][vc_row full_width=”stretch_row” content_placement=”middle” css=”.vc_custom_1678088742381{padding-top: 0px !important;background-color: #eff3fa !important;}”][vc_column][vc_column_text]The more commonly available treatment modality for ablative radiation therapy is the photon. However, photon therapy has a deposit dose along the exit beam path beyond the target volume, leading to an unwanted dose to the nontarget liver and other surrounding organs. In contrast, proton radiotherapy offers dosimetric advantages because of its superior physical properties. A proton beam has a finite range of energy deposition with no exit dose after the target. This physical advantage over photon beams could reduce the unwanted spreading of the dose to the surrounding normal liver and adjacent organs.<\/span><\/p>\n

There have only been two retrospective studies showing the clinical benefits of proton radiotherapy over photon radiotherapy. The Massachusetts General Hospital study from the Massachusetts General Hospital (MGH) demonstrates survival benefit, which may be driven by decreased incidence of posttreatment liver decompensation. In Taiwan, a propensity score-matched cohort study based on a multi-institution medical organization research database, demonstrated that proton radiotherapy could deliver a higher radiation dose than photon radiotherapy without increasing the risk of RILD and result in a better overall survival rate. (3)<\/span><\/p>\n

Although dosimetric and retrospective studies have demonstrated an advantage in using proton therapy, there has been no randomized controlled trial comparing proton and photon ablative radiation therapy. Therefore, in this study, we conducted a randomized controlled trial to investigate and compare the clinical outcomes of the two modalities.<\/span>[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_column_text]Eligibility<\/strong><\/p>\n

To be eligible for this study, patients must meet following requirements, including:
\n<\/span><\/p>\n